 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--ImmunoPrecise Antibodies Ltd. the Company or IPA NASDAQ: IPA TSX Venture: IPA announced preliminary, preclinical data in hamsters of IPAs proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPAs TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SA 